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Abstract: 
 
Epithelial ovarian cancer has the highest mortality rate of all gynaecological malignancies.  
Most women present with advanced disease and develop a recurrence after radical surgery 
and chemotherapy. Improving the results of first- or subsequent line chemotherapy has been 
slow and novel approaches to systemic treatment are needed. Ovarian cancer is a 
heterogeneous disease with complex molecular and genetic changes. Understanding these 
better will provide information on the mechanisms of resistance and opportunities to target 
therapy more rationally, exploiting specific changes in the tumour.  Here we review targeted 
approaches to therapy, focussing on targeting angiogenesis and inhibition of DNA repair, two 
areas that show promising activity. Additionally, we review studies that are underway 
targeting the cell cycle and signalling pathwayYs as well as immunotherapeutic strategies. 
Many of these innovative approaches already demonstrate promising activity in ovarian 
cancer, and have the potential to improve the outcome in women with ovarian cancer.  
 
Keywords: targeted therapy, ovarian cancer, anti-angiogenesis, PARP inhibitor, 
immunotherapy 
 
 
 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 3 
Introduction: 
 
Epithelial ovarian cancer (EOC) is one of the most common gynaecological malignancies and 
most women present with advanced disease.  It has a high mortality rate and is the 5
th
 most 
common cause of cancer death in women [1].   Whilst the survival of patients with advanced 
ovarian cancer has increased over the last two decades through better surgery and more 
chemotherapy options, cytotoxic drug therapy has been non-selective often resulting in 
significant toxicity and short-lived anti-tumour responses. Most women with ovarian cancer 
will suffer a tumour recurrence after first-line therapy and in almost all of them, resistance to 
chemotherapy will eventually develop leading to death from ovarian cancer. There has been a 
significant increase in the knowledge of molecular and genetic changes in ovarian, and this 
has led to the development and evaluation of targeted therapies in this disease. Here we 
review how these new drugs are being used and investigated in women with ovarian cancer, 
and their contribution thus far to improving the response to therapy and disease outcome. 
 
1.Angiogenesis 
 
Solid tumour growth and progression is reliant on neovascularisation [2].   Angiogenesis is 
complex and is regulated by several different endogenous pro-angiogenic and anti-angiogenic 
factors.  Key angiogenic molecules include vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and angiopoietin (Ang 
1 and 2) [3]. The Ang 1/2 –Tie 2 receptor axis is a VEGF independent signalling pathway, 
which mediates vascular re-modelling [3]. Folkman et al proposed that a fine balance exists 
between angiogenic inhibitory and stimulatory factors. In normal tissues angiogenesis is 
turned off. However, an ‘angiogenic switch’ can occur in tumours leading to the production 
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of pro-angiogenic stimuli causing growth of the tumour and its vasculature [4].  These new 
blood vessels often have defective basement membranes, are thin walled and leaky, allowing 
cancer cells to enter the circulation and metastasise [5].    
 
In EOC, angiogenesis plays a role in tumour growth, formation of ascites and metastasis.  
The vasculature within the tumour is more structurally and functionally abnormal, with 
tortuous, leaky, dilated and immature blood vessels with poor flow.  The endothelial cells 
within these vessels are more dependent on VEGF for survival when compared to more 
mature blood vessels elsewhere in the body [6].  
 
The VEGF family of growth factors and its receptors are the most important signalling 
pathways in tumour angiogenesis [6].  VEGF-A is the best-characterised VEGF ligand and 
appears to play a dominant role in angiogenesis by binding to VEGF receptor tyrosine 
kinases (VEGFR). In angiogenesis the two most important members of the VEGFR family 
are VEGFR1 (Flt-1) and VEGFR2 (Flk-1).  VEGFR2 has the most direct effect on 
angiogenesis, by mediating the angiogenic and permeability enhancing effects of VEGF. The 
role of VEGFR1 is less direct, and may play a role in angiogenesis by recruiting bone 
marrow derived cells and monocytes into the tumour vasculature [7].  
 
2. Vascular Endothelial Growth Factor (VEGF) inhibition 
 
Inhibition of VEGF restores the balance between pro-angiogenic and anti-angiogenic factors, 
thereby normalising tumour blood vessel structure and function [8].  This influences tumour 
growth and is thought to improve the delivery of chemotherapy drugs to tumours and to 
decrease their metastatic potential.  
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There is a high expression of VEGFR in ovarian cancer and many tumours produce high 
levels of VEGF. Inhibitors of VEGF signalling such as the recombinant monoclonal 
antibody, bevacizumab that binds to circulating VEGF-A and aflibercept, a fusion protein 
that binds directly to VEGF preventing it from binding to its receptors, have been extensively 
evaluated in ovarian cancer treatment.  Another strategy that has been explored is to use a 
peptide-Fc fusion protein, trebananib, which binds to Ang 1 and Ang 2, preventing its 
interaction with the Tie 2 receptor [3]. 
 
2.1 Bevacizumab  
 
In ovarian cancer, bevacizumab has been explored as a single agent, in combination with 
chemotherapy, and as maintenance treatment post chemotherapy. It has been studied 
extensively in the setting of first-line platinum-based chemotherapy, ‘platinum-sensitive’ 
(relapse > 6months following completion of platinum based treatment) and in ‘platinum-
resistant’ disease (relapse ≤6 months of completing platinum based treatment).  For a 
summary the pivotal trials described below see table 1.      
 
ICON7 [9] and GOG 218 [10] are the two key first-line studies investigating the addition of 
bevacizumab to chemotherapy following surgery for advanced ovarian cancer.  In ICON7, 
patients were randomised to standard 6 cycles of three-weekly carboplatin and paclitaxel with 
or without intravenous bevacizumab 7.5mg/kg every three weeks followed by maintenance 
bevacizumab for up to 12 months.  The median progression free survival (PFS) was 17.5 
months with standard therapy alone versus 19.9 months in the bevacizumab arm (HR 0.87; 
p=0.04).    The benefit from bevacizumab was greater in women at higher risk of progression 
due to incomplete cytoreductive surgery ( ≥1 cm residual disease) or FIGO stage IV disease. 
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In this group the PFS was 14.5 compared to 18.1months in women receiving bevacizumab. 
No difference was seen in the median overall survival (OS), which was 58 months. However, 
in the higher risk subgroup there was a 9.5 month difference in the median OS, 30.2 vs 39.7 
months (p=0.03) in women receiving bevacizumab [11].   The second trial GOG 218 was a 
US-led 3-arm randomised placebo-controlled study.  Each arm received 6 cycles of standard 
three-weekly carboplatin and paclitaxel.  Arm 1 received chemotherapy with placebo, and 
placebo maintenance for 15 months, arm 2 chemotherapy plus bevacizumab (15mg/kg) from 
cycle 2-6 then switching to placebo maintenance as above, and women in arm 3 received 
chemotherapy plus bevacizumab from cycle 2-6 followed by bevacizumab maintenance. 
Compared to the control (arm 1) a significant improvement in PFS was seen only in women 
receiving bevacizumab with chemotherapy and as maintenance. The difference in median 
PFS in this group compared to placebo was 3.9 months and there was no difference in OS 
(table 1 for details) [10].   
 
In women with ‘platinum-sensitive’ recurrent disease, the OCEANS trial [12] evaluated the 
addition of bevacizumab to chemotherapy and then as maintenance post chemotherapy until 
disease progression.  Patients were randomised to three-weekly chemotherapy (gemcitabine 
1000mg/m
2
 D1,8 and carboplatin AUC 4) with bevacizumab 15mg/kg or placebo. A 4 month 
improvement in median PFS was seen that was statistically significant, but there was no OS 
benefit [13].  Similar results were seen in GOG 0213 that compared three-weekly carboplatin 
and paclitaxel with or without bevacizumab. In this trial there was a 3.4 month significant 
difference in median PFS. Preliminary results reported a trend towards an improvement in 
median OS and the benefit was unaffected by prior use of bevacizumab [14]. 
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In women with ‘platinum-resistant’ relapse, the phase III randomised AURELIA trial [15] 
evaluated the addition of bevacizumab to a choice of chemotherapy regimens (weekly 
paclitaxel, pegylated liposomal doxorubicin [PLD] or topotecan, given either over five days, 
or weekly). Overall, there was a 3.3month improvement in median PFS when bevacizumab 
was added to chemotherapy which was significant (table 1). Bevacizumab was not continued 
as maintenance therapy but the benefit in PFS and quality of life was seen consistently across 
all subgroups, particularly in patients with ascites, which is associated with a poorer 
prognosis [16]. The greatest difference in PFS was seen in patients receiving weekly 
paclitaxel [17]. There was no statistically significant improvement in OS but the trial was not 
designed to show a difference in OS and 40% of patients receiving chemotherapy alone were 
subsequently treated with bevacizumab.   
 
Toxicities of VEGF-Inhibitors include hypertension, impaired wound healing, proteinuria, 
increase risk of thromboembolism and gastrointestinal toxicities. This includes the rare but 
serious complications of perforation and fistulae and a decision to use bevacizumab needs to 
take note of the volume of serosal disease, particularly thickening of the sigmoid colon due to 
tumour, as the risk of perforation is greater in patients with large amounts of serosal disease.  
 
Despite evidence of activity in different phases of the treatment pathway, there is no 
international consensus about when the value of bevacizumab therapy is greatest. This is 
reflected in the license, with indications varying across the world.  
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2.2 Aflibercept  
 
Intravenous aflibercept has been evaluated in recurrent ovarian cancer both as a single agent 
and in combination with chemotherapy.  In ‘platinum-resistant’ disease the response rate to 
single-agent aflibercept is <5% [18], although in combination with docetaxel, the response 
rate has been reported to be 54%. However, these patients were not as heavily pre-treated as 
those enrolled in the single agent phase II study and 13/46 (28%) patients had ‘platinum-
sensitive’ disease [19].  Aflibercept prolongs the time to repeat paracentesis in women with 
recurrent symptomatic ascites, when compared to placebo, with a median time to repeat 
paracentesis of 55.1 days and 31.8 days respectively [20].   However, the risk of fatal bowel 
perforation is increased with aflibercept and the risk-benefit balance needs to be carefully 
considered [20].   
 
2.3 Trebananib  
 
Trebananib has been evaluated in a series of trials: TRINOVA-1, a randomised phase III trial 
combining trebananib with weekly paclitaxel in 919 women with recurrent ovarian cancer 
relapsing after a platinum-free interval of <12 months.  Compared to placebo, trebananib 
significantly prolonged the median PFS (7.2 vs 5.4 months respectively; HR 0.66; p<0.0001) 
but no OS advantage was seen (19.3 vs 18.3 months; HR 0.95; p=0.55). The main toxicity 
observed was oedema [21].  Results from two other phase III studies of trebananib in ovarian 
cancer are pending; TRINOVA-2 (NCT01281254) a study of PLD with or without trebananib 
also in recurrent ovarian cancer, and TRINOVA-3 (NCT01493505) a study in which 
trebananib was combined with first-line chemotherapy.   
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3. Multi-targeted anti-angiogenic agents 
 
Tyrosine kinase inhibitors (TKIs) are multi-targeted, low-molecular weight drugs, which bind 
to the ATP-binding catalytic site of the tyrosine kinase domains of VEGF-R and other 
tyrosine kinases.  These oral agents often target more than one receptor tyrosine kinase [4].  
Examples include sorafenib, cediranib, pazopanib and nintedinib, all of which have been 
shown to have activity in ovarian cancer [3].  It is attractive to use a drug that targets more 
than one pathway, as this could lead to a greater inhibition of angiogenesis compared with 
single pathway inhibitors such as bevacizumab.  However, while the therapeutic response 
may be greater, their more complex mechanism of action may increase toxicity [4] (table 2). 
 
3.1 Pazopanib  
 
Pazopanib targets several angiogenic receptors including downstream signals of VEGFR 
1,2,3, PDGFR and c-kit [22, 23].  Pazopanib has been evaluated in recurrent ovarian cancer 
and as maintenance therapy in the first-line setting. In MITO11 [24], an open-label phase II 
trial, patients with ‘platinum-resistant’ ovarian cancer were randomised to weekly paclitaxel 
with or without pazopanib.  There was a 2.9 month improvement in PFS in the combination 
arm (median 6.3 vs 3.4 months) that was statistically significant.   In the phase III study, 
AGO-OVAR-16, patients who did not have tumour progression at the end of first-line 
therapy, were randomised to maintenance pazopanib or placebo for up to 24 months.  There 
was an improvement of 5.6 months in the median PFS in patients on pazopanib compared to 
placebo, however this did not translate into an OS benefit and there were much higher grade 
3/4 adverse event rates in patients on pazopanib, for example, hypertension, neutropenia, 
liver toxicity, diarrhoea, fatigue, thrombocytopenia and palmar-plantar erythema. The dose of 
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pazopanib was reduced in 58%, and 33.3% discontinued treatment secondary to toxicity 
compared to 5.6% in the placebo arm [25]. Consequently, the drug has not been submitted for 
Market Authorisation. 
 
3.2 Nintedanib  
 
Nintedanib (BIBF 1120) is a triple angiokinase inhibitor, inhibiting VEGFR, FGFR and 
PDGFR, which all contribute to tumour angiogenesis [26].   Activity of the drug in a 
randomised phase II trial [27] led to a phase III study in first-line therapy.  
 
In the AGO-OVAR 12 nintedinib or placebo was combined with carboplatin and paclitaxel 
and then continued as maintenance for up to 120 weeks. There was a 1.2 month difference in 
median PFS, significantly longer in patients receiving nintedanib compared with placebo but 
this small difference was thought to be insufficient for further development in this indication 
[28].  Hypertension is uncommon with this drug and most of the adverse events were 
gastrointestinal, with 21% of patients in the nintedanib arm experiencing ≥ grade 3 diarrhoea 
[28]. Trials continue in patients with ‘platinum-resistant’ ovarian cancer and in patients with 
clear cell tumours of the ovary or endometrium. 
 
3.3 Cediranib  
 
Cediranib, an oral inhibitor of VEGFR-1, 2 and 3 is also active in recurrent ovarian cancer. 
The magnitude of response of this drug was modest but sufficient for exploration in a phase 
III trial [29].  Cediranib was evaluated in ICON6, an academic-led randomised, three arm, 
double-blind placebo-controlled trial in ‘platinum-sensitive’ ovarian cancer.  The design 
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allowed comparison of the effect of cediranib with chemotherapy, and as maintenance 
therapy [30]. The original trial design was changed when the manufacturer temporarily 
ceased production of the drug, and the main comparison using a smaller number of patients 
was between chemotherapy and concurrent cediranib followed by maintenance cediranib 
with chemotherapy and placebo throughout. There was a significant improvement in median 
PFS, from 8.7 to 11 months (HR 0.56; p<0.0001). OS data were immature at the time of 
publication.  However, toxicity, principally fatigue, diarrhoea and hypertension were 
significant with 32% of patients discontinuing cediranib during treatment. This was most 
evident when cediranib was given with chemotherapy [30]. A submission for Market 
Authorisation in patients was recently withdrawn by the manufacturer. However, cediranib is 
an active drug and continues to be evaluated in ovarian cancer (see below). 
 
4. Targeting the folate receptor  
 
The folate cycle maintains essential metabolic reactions required for rapidly growing cells. 
Once folates enter a cell, they have a crucial role in the biosynthesis of purines and 
thymidine, required for DNA synthesis, repair and methylation [31-34]. The alpha isoform of 
the FR (αFR) transports folates by receptor-mediated endocytosis [35] and is selectively 
overexpressed in a number of solid tumours, including non-mucinous ovarian cancers [36]  
 
Farletuzumab (MORAb-003), a humanised monoclonal antibody to αFR leads to cell-
mediated cytotoxicity, complement dependent killing and non-immune mediated αFR-
dependent inhibition of growth under folate limiting conditions [36, 37].  An initial phase II 
study looking at the addition of farletuzumab to chemotherapy followed by maintenance 
therapy in ‘platinum-sensitive’ ovarian cancer showed promising activity with an improved 
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overall response rate compared to historical controls [38]. However, the benefit was not 
confirmed in a subsequent phase III trial [39].  
 
In a different folate-targeting strategy, vintafolide (EC145), a folate-conjugated vinca 
alkaloid that targets FR-expressing cells was explored in a randomised phase II trial in 
‘platinum-resistant’ ovarian cancer. In the PRECEDENT trial patients were randomised to 
PLD alone, or in combination with vintafolide [40].  The study met its primary end point, 
demonstrating a 2.3 month improvement in median PFS in the experimental arm (5.0 versus 
2.7 months; HR 0.63; p=.031]) but the subsequent randomised phase III trial (PROCEED) 
[41] was  stopped early because a pre-specified interim analysis showed no benefit.  
 
5. Homologous recombination deficiency (HRD) and ovarian cancer 
 
Normal cellular function and genomic stability is maintained by recognition and subsequent 
repair of DNA damage that occurs in all cells [42]. There are 450 known genes implicated in 
DNA damage response and repair [43] and they are sub-divided into 5 distinct pathways 
which are responsible for repair of specific types of DNA damage [44].  Double stranded 
DNA breaks (DSB) are the most lethal insult to the genome and if left unrepaired, genomic 
instability and cell death will occur [45]. They can be repaired by several different pathways, 
the main one being homologous recombination repair (HRR).  A large proportion of DSB 
arise during DNA replication when a replication fork encounters an unrepaired single strand 
break (SSB).  The HRR pathway, together with PARP-1, a nuclear enzyme, is especially 
important in repairing these collapsed replications forks [46, 47]. If HRR is defective (HRD), 
cells are dependent on alternative pathways for repair. These are significantly impaired by 
inhibition of PARP enzymes. BRCA1 and BRCA2 proteins play an important role in HRR, 
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and when mutated, cells have HRD that can be selectively exploited by PARP inhibitors, 
leading to unrepaired, or poorly repaired DNA and tumour synthetic lethality [48].  
 
6. Ovarian cancer and PARP inhibitors (PARPi) 
 
Germline mutations of BRCA1 and BRCA2 genes are present in about 15% of high-grade 
serous ovarian cancer (HGSOC), the most common histological subtype. Whilst this is the 
most common cause of HRD, somatic mutations of the BRCA genes are found in about 5% 
of these tumours as well as mutations of other key HRR genes, such as RAD51. It has been 
estimated that approximately 50 % of HGSOC tumours have HRD [49, 50] sometimes 
referred to as ‘BRCAness’ [51]. Targeting HRD with PARPi, in both BRCAmut (BRCA 
mutated) and BRCA
wt
 (BRCA wild-type) ovarian cancer is an important therapeutic approach 
that is being developed in high-grade ovarian cancers.  Several oral PARPi are being 
developed, and are summarised in table 3. 
 
6.1 Olaparib  
 
Much of the initial investigations with PARPi and the greatest body of information comes 
from studies with olaparib (AZD2281). Frequent and sometimes durable responses were seen 
in Phase I trials in patients with BRCA
mut
 cancers [52, 53].  Subsequent phase II trials in 
BRCA
mut
 advanced breast and ovarian cancer confirmed the activity of olaparib monotherapy 
[54, 55]. 
 
The first randomised trial, Study 12 compared olaparib with PLD in women with a BRCA
mut
 
recurrent ovarian cancer [56].  It was a small trial with three arms (two different doses of 
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olaparib, 200mg bd and 400mg bd,) continuously were compared with PLD (50mg/m
2 
IV) 
every four weeks in patients with a BRCA
mut relapsing ≤ 12 months after prior therapy. There 
was no statistically significant difference in PFS between the olaparib and PLD arms. 
Olaparib was active, as predicted but the outcome of patients treated with PLD was better 
than expected and confounded the ability to see a benefit in favour of olaparib [56]. 
 
Clear activity of single-agent olaparib in BRCA
mut 
was also demonstrated in Study 42, a 
multicentre phase II trial that enrolled 298 patients with germline BRCA1/2 mutations and 
recurrent breast, ovarian, pancreatic or prostate cancers [57]. Within this trial there were 193 
patients who had received ≥ 3 lines for chemotherapy for ovarian cancer and the overall 
response rate was 34%, median duration of response 7.9 months [58].On the basis of these 
data the US FDA granted approval for single agent olaparib in this group. 
 
6.2 Olaparib maintenance therapy 
 
Most of the studies with olaparib and other PARPi have focussed on using these drugs as 
maintenance therapy following chemotherapy. The original trial, study 19, included patients 
with platinum-sensitive HGSOC who had responded to platinum-based therapy. The trial was 
designed to investigate maintenance olaparib in a broad setting, including patients with or 
without a BRCA
mut
. The inclusion of the latter group was based on emerging data showing 
single agent activity of olaparib in patients without a BRCA mutation [59]. Study 19 
randomly assigned 265 patients to olaparib capsules (400mg BD) or placebo within 8 weeks 
of completing platinum-based therapy. There was a significant difference in PFS with 
olaparib compared to placebo, measured from the start of maintenance therapy (8.4 vs 4.8 
months, HR 0.35; p<.001]) [60].   
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At study entry, the BRCA mutation status was known for only 98 (37%) of the patients.   A 
later analysis of BRCA status in germline and or tumour was carried out and BRCA status 
became available for 254 (96%) of patients. A pre-specified retrospective analysis of all 
efficacy endpoints was done [61].  In the mutated-BRCA (germline or somatic BRCA
mut
) 
group of 136 patients there was an even greater increase in the median PFS from start of 
maintenance with olaparib compared to the placebo group (11.2 vs 4.3 months; HR 0.18; 
p<0.0001]).  However, there was also a benefit in the BRCA
wt
 group (HR 0.54; p=0.0075).   
 
Exploratory end-points such as the time to first subsequent therapy or death (TFST) and time 
to second subsequent therapy or death (TSST) were significantly improved with olaparib 
[61], adding weight to the overall clinical value of this therapy in the absence of a significant 
OS benefit. It is noteworthy that in patients with a BRCA
mut
 the start of the next line of 
therapy was delayed by a median of 9.4 months (median PFS 15.6 versus 6.2 months; HR 
0.32; p<0.0001). In the third interim survival analysis, there is a trend for a survival benefit in 
the BRCA
mut
 group but it does not reach statistical significance (34.9 vs 30.2 months; HR 
0.62; p=0.02). The reasons for this include the small sample size, multiple survival analyses, 
and most importantly crossover to a PARPi by 23% of patients [62]. However, the longer 
follow up at this analysis identified that 13% of all patients (15% of BRCA
mut 
patients) 
received maintenance olaparib for at least 5 years.   The most common toxicities, with an 
incidence of ≥10% in the olaparib group, were nausea, vomiting, fatigue and anaemia, most 
of which were grade ≤2 [60]. 
 
Based on the results of this trial, the drug received marketing authorisation as maintenance 
therapy in mutated-BRCA HGSOC from the EMA and many other international regulatory 
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authorities. Two phase III trials of olaparib maintenance have now been completed, using 
tablets, 300mg bd, rather than capsules.  SOLO-1 (NCT01844986) recruited patients with 
newly diagnosed BRCA
mut
 ovarian cancer, who responded to first line platinum therapy; the 
results are pending. The top-line results for SOLO-2 (NCT01874353) in BRCA
mut
 high-grade 
‘platinum-sensitive’ ovarian cancer after ≥2 lines of platinum therapy have reported a 
favourable outcome but the results have not yet been presented.  
 
6.3 Olaparib combination with molecularly targeted therapies 
 
After showing promising activity in a phase I trial [63], the combination of cediranib with 
olaparib was tested in a phase II trial [64].  Patients with ‘platinum-sensitive’ ovarian cancer 
were randomly assigned to receive olaparib capsules alone (400mg BD) or olaparib (200mg 
BD) and cediranib (30mg od).  The trial, without intravenous cytotoxic chemotherapy 
resulted in a significant improvement in PFS in the combination arm.  The median PFS was 
17.7 months versus 9.0 months; HR 0.42; p=0.005). A post-hoc analysis suggested the 
greatest benefit was in the subgroup of BRCA
wt 
or unknown.  However, 70% of patients in 
the combination arm experienced ≥grade 3 AEs, including diarrhoea, fatigue and 
hypertension. Nevertheless, the encouraging results have led to randomised trials in recurrent 
ovarian cancer, comparing this combination with chemotherapy NRG-GY004 
(NCT02446600), and as maintenance in the planned ICON9 trial. A first-line trial, PAOLA-1 
is comparing the combination of olaparib and bevacizumab to bevacizumab maintenance 
alone following carboplatin/paclitaxel and bevacizumab (NCT02477644).  
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6.4 Niraparib  
 
The recently reported results of the maintenance trial, NOVA using niraparib (MK4827), an 
active oral, selective PARP1 and 2 inhibitor [65] have confirmed the value of maintenance 
therapy and added weight to the broader use of PARPi in both germline BRCA
mut 
(gBRCA
mut
) and non-gBRCA
mut
 HGSOC cohorts who have responded to their most recent 
platinum-based chemotherapy. The NOVA trial (NCT01847274) is a double-blind controlled 
phase III maintenance study of niraparib vs placebo and enrolled these two cohorts, 
randomising patients 2:1 to niraparib 300mg once daily or placebo. In the 203 patients with 
gBRCA
mut
 niraparib led to a significant prolongation in the PFS (median PFS after enrolment 
21 months versus 5.5 months with placebo; HR 0.27; p< 0.001). Similarly, in the 350 non-
gBRCA
mut
 patients there was a significant benefit for niraparib (median PFS 3.9 versus 9.3 
months; HR 0.45; p<0.001) [66].In an exploratory analysis, tumours were tested for HRD 
using the MyChoice assay (Myriad Genetics). Significant benefit in PFS was seen across all 
subgroups, including somatic BRCA
mut
, (HRD positive), BRCA
wt
 HRD positive and non-
gBRCA
mut
 HRD negative groups. The effect of niraparib was less in HRD negative tumours 
and it remains to be seen whether the sensitivity of this assay is sufficient for it to distinguish 
patients who may or may not have a clinically meaningful benefit from niraparib. The most 
common adverse effects were thrombocytopenia, often occurring early, anaemia and 
neutropenia, which could usually be managed by dose reductions. 
 
As with olaparib, combination studies of niraparib with bevacizumab have started and there 
are plans to conduct studies in the first-line setting. The drug has yet to be licensed in ovarian 
cancer, but the results of the NOVA trial have confirmed the significant benefit of PARPi in 
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the treatment of recurrent ovarian cancer and value of this drug in patients without a germline 
or somatic BRCA mutation.   
 
6.5 Rucaparib  
 
In addition to inhibition of PARP 1 and 2  rucaparib also inhibits other PARP isoforms,  
tankyrase 1 and 2 (TNKS1/2) [67].  Phase I studies identified 600mg BD as the optimal dose 
[68] that has been taken forward in ovarian cancer patients.  The drug has been given 
‘breakthrough’ designation by the FDA for use as a single agent in patients with BRCAmut 
who have had at least 2 lines of platinum-based chemotherapy [69]. ARIEL 2 
(NCT01891344), is a phase II study designed to identify patients who are likely to respond to 
rucaparib, based on biopsies to characterise a biomarker test for HRD that measures the 
degree of genomic scarring, expressed as Loss of Heterozygosity (LOH), a marker of tumour 
HRD.  Three pre-defined HRD subgroups, tumour BRCA
mut
, BRCA-like 
(BRCA
wt
/LOHhigh) and biomarker negative (BRCA
wt
/LOHlow) were identified. Two-
hundred and six patients were enrolled and the median PFS was 9.4 vs 7.1 vs 3.7 months, 
with ORR of 82%, 45% and 21% in the BRCA
mut
, BRCA-like and biomarker negative 
groups respectively. Robust activity was seen in both germline and somatic BRCA
mut
 patients 
and the median duration of response was 9.3 months, but is still ongoing [70]. Rucaparib is 
generally well tolerated, with the most common adverse events being nausea, fatigue and 
increase in ALT/AST [70]. The HRD algorithm will be applied prospectively to ARIEL 3 
(NCT01968213), a randomised phase III maintenance study of rucaparib vs placebo in high 
grade ovarian cancer, BRCA
mut 
or BRCA
wt
 who have responded to ≥2 platinum regimens 
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6.6 Veliparib  
 
Veliparib (ABT-888) is an orally bioavailable small molecule that inhibits PARP1 and 2 and 
is able to penetrate the blood brain barrier [71].  Phase I studies have evaluated its activity in 
combination with cytotoxic chemotherapy, with myelosuppression being the most common 
toxicity [72-74].  Responses were observed in BRCA
mut
 cancers [74].  Single agent veliparib 
is active in BRCA
mut
 recurrent ovarian cancer as shown in a multicentre phase II clinical trial 
[75].  However, a phase II trial conducted to evaluate its activity in combination with oral 
cyclophosphamide in BRCA
mut
 ovarian cancer revealed no improvement in response rate or 
median PFS compared to cyclophosphamide alone [76]. A three-arm phase III placebo 
controlled trial of carboplatin and paclitaxel with placebo, or veliparib followed by 
maintenance placebo, or the combination followed by veliparib maintenance in first line 
treatment of advanced HGSOC is currently recruiting patients (NCT02470585).   
 
6.7 Talazoparib  
 
Talazoparib (BMN 673) inhibits PARP1/2 and pre-clinical studies have shown it to be more 
potent than other PARPi [77].  In a phase I dose escalation study, responses were seen in 
11/17 BRCA
mut
 ovarian cancers.  The recommended dose is 1000mcg/day due to dose-
limiting thrombocytopenia [78]. A phase II study for single agent talazoparib in patients with 
BRCA
mut
 advanced solid tumours is currently underway (NCT01989546) and importantly, 
the drug is being examined in patients who have previously been treated with a PARPi 
(NCT02326844).   
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7. Ovarian cancer and the immune system  
 
The success of immune checkpoint inhibition in melanoma and lung cancer [79-83] has 
inspired further investigation of these agents in multiple other solid tumours, including 
ovarian cancer.   Tumour cells are able to ‘escape’ the immune system and one of the most 
important components is an immunosuppressive co-signal (immune checkpoint) facilitated by 
programmed cell death 1 (PD-1) and it’s ligand PDL-1 [84].  PD-1 is mainly expressed on T-
cells and PDL-1 is expressed on numerous types of cancer cells and on tumour infiltrating 
immune cells in the tumour microenvironment [84].  In ovarian cancer, the presence of 
tumour infiltrating lymphocytes (TILs) is associated with a better outcome [85].  Nivolumab, 
pembrolizumab and avelumab are checkpoint inhibitors being trialled in ovarian cancer.   
 
Intravenous nivolumab, an anti-PD-1 antibody was given to 20 patients with ‘platinum-
resistant’ ovarian cancer using either 1mg/kg or 3mg/kg two-weekly infusions.  The overall 
response rate was 15%.  No correlation was found between clinical response and PDL-1 
expression [86]. 
 
A phase Ib trial with the humanized monoclonal anti-PD-1 antibody, pembrolizumab 
included patients with ovarian cancer (KEYNOTE-028) (NCT02054806). In PDL-1+ve 
(PDL-1 expression ≥ 1%) there were 26 patients with advanced ovarian cancer and the 
overall response rate was 11.5% [87].  Pembrolizumab is undergoing further evaluation in a 
phase II trial in ovarian cancer (KEYNOTE-100) (NCT02674061). 
 
Avelumab (MSB0010718C), a fully human anti-PDL-1 antibody, has been evaluated in the 
JAVELIN Solid tumour phase Ib study (NCT01772004).  One hundred and twenty-four 
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unselected patients with heavily pre-treated ‘platinum-resistant’ ovarian cancer patients were 
enrolled, making this the largest reported dataset of patients with ovarian cancer and immune 
checkpoint inhibitors.  The overall response rate was 9.7% [88].  The most common 
treatment related adverse events were fatigue, nausea/vomiting, diarrhoea/constipation, chills, 
infusion-related reactions, rash and hypothyroidism.  Whilst tumour response rates are 
modest, some patients experience long responses to all these checkpoint inhibitors.  Phase III 
trials with avelumab in ovarian cancer are currently underway.  JAVELIN Ovarian 200 
(NCT02580058) is a trial of avelumab +/- PLD vs PLD alone in ‘platinum-resistant’ ovarian 
cancer and JAVELIN Ovarian 100 (NCT02718417) is a three-arm trial evaluating avelumab 
in combination with and/or following first line chemotherapy for advanced ovarian cancer.   
9. Phosphatidylinositol 3-Kinase (PI3K) inhibitors 
The PI3K/AKT/mTOR is a complex pathway that regulates a number of crucial cellular 
functions, including cell growth, migration, survival and angiogenesis [89].  Changes in the 
pathway and molecular alterations, such as gene mutations and amplifications contribute to 
oncogenesis and resistance to anti-cancer drugs.  It is an important therapeutic target in 
cancer, however, there has been little success of these agents in ovarian cancer to date [90]. 
10. Wee1 inhibitors  
When DNA is damaged, there are various checkpoints that arrest the cell cycle to allow for 
this damage to be repaired.  The G1 checkpoint is mainly regulated by the p53, which is 
commonly mutated in cancer cells.  p53-deficient tumours therefore rely on the G2/S 
checkpoint for DNA damage repair [91].  If the G2 checkpoint is impeded, then p53 deficient 
cells may become more sensitive to DNA-damaging drugs [92]. Wee1 is a tyrosine kinase 
that phosphorylates CDC2, which inactivates the CDC2/cyclin B complex required for the 
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normal functioning of the G2 checkpoint. AZD1775 (formally MK-1775) is a potent Wee1 
inhibitor. In combination with carboplatin, it has been shown to have promising activity in 
‘platinum-resistant’ disease (relapse <3 months following completion of first line therapy) 
with p53 mutations.  The most common toxicities reported were myelosuppression, fatigue, 
diarrhoea, nausea and vomiting [93].  
11. Summary 
This review highlights the paradigm shift in the treatment of ovarian cancer.  Although 
chemotherapy remains the backbone of treatment, novel targeted therapies, both in 
combination with chemotherapy and alone, have demonstrated significant improvements in 
PFS and the ‘one size fits all’ treatment approach for ovarian cancer is no longer applicable.  
Bevacizumab are olaparib are two drugs directed against the angiogenic and DNA damage 
response pathways that have been approved for treatment of ovarian cancer. Olaparib is the 
first drug directed against a predictive marker which allows the selection of patients likely to 
achieve the greatest benefit. Encouraging results are emerging from studies with other PARP 
inhibitors and these are likely to widen the use of these drugs in ovarian cancer. A benefit is 
seen not only in patients with a BRCA mutation, but also in a larger number of patients 
within an HRD positive group. Combinations of PARP inhibitors with other molecularly 
targeted therapies, especially anti-angiogenic drugs are also showing promise.  The most 
recent development in therapeutics has been investigation of immune checkpoint inhibitors. 
Their role in treatment of ovarian cancer is unclear, but many trials are in progress and there 
is hope that the benefit of these drugs seen in other tumours may extend into the treatment of 
ovarian cancers. 
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Table 1: Phase III trials of bevacizumab in advanced ovarian cancer. 
Study Population Treatment Median PFS (months) Median OS (months) 
ICON7 [9] 
 
First-line high risk stage I-IIA 
or stage IIB-IV ovarian 
cancer (n=1528) 
CP vs CP + bevacizumab (7.5mg/kg) followed 
by maintenance bevacizumab 
22.4 vs 24.1 
(HR 0.87; p=0.04) 
58.6 vs 58.0 (p=0.85) 
Poor prognosis group:  
30.2 vs 39.7 (p=0.03) 
GOG 218 [10] 
 
First-line stage III 
(incompletely resected) and 
stage IV ovarian cancer 
(n=1873) 
CP vs CP + bevacizumab (15mg/kg) + 
maintenance + PL vs CP + bevacizumab 
(15mg/kg) + maintenance bevacizumab 
10.3 vs 11.2 vs 14.1 
(HR 0.72; p<0.001) 
39.3 vs 38.7 vs 39.7  
(HR 0.95; p=0.45) 
OCEANS [13] 
 
PSROC (n=484) GC + PL vs GC + bevacizumab (15mg/kg) 8.4 vs 12.4  
(HR 0.48; p<.0001) 
32.9 vs 33.6 
(HR 0.95; p=0.65) 
GOG 0213 [14] 
 
PSROC (n=674) CP vs CP + bevacizumab (15mg/kg) 10.4 vs 13.8  
(HR 0.61; p<.0001) 
37.7 vs 42.2  
(HR 0.83; p=0.056) 
AURELIA [15] 
 
PRROC (n= 361) CT vs CT + bevacizumab (10mg/kg q2/52 or 
15mg/kg q3/52) 
3.4 vs 6.7  
(HR 0.48; p<.001) 
13.3 vs 16.6  
(HR 0.85; p<.174) 
 
PSROC – ‘platinum-sensitive’ recurrent ovarian cancer; PRROC – ‘platinum-resistant recurrent’ ovarian cancer; CP – carboplatin/paclitaxel;  
PL – placebo; GC – gemcitabine/carboplatin; CT – chemotherapy [ choice of weekly paclitaxel, PLD, topotecan];  
q2/52 – 2 weekly; q3/52 – 3 weekly; 
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Table 2: VEGFR-Inhibitors in ovarian cancer 
Agent Trial Line of treatment PFS (months) 
Sorafenib  
 
Randomised phase II [94] 
CP +/- sorafenib followed by maintenance sorafenib for a total of 1yr 
First line  15.4 vs 16.3 
(p=0.38) 
Pazopanib  Randomised Phase II: MITO 11 [24] 
Pazopanib + paclitaxel vs paclitaxel alone 
Phase III maintenance study: AGO-OVAR-16 [25] 
Pazopanib v placebo maintenance 
PRROC 
 
First line 
6.3 vs 3.4  
 
17.9 vs 12.3  
HR 0.77; p=0.0021 
Nintedanib Phase III: AGO-OVAR-12 [28] 
CP +/- nintedanib followed by maintenance nintedinib or placebo  
First line 17.2 vs 16.6 
HR 0.84; p=0.024 
Cediranib Phase III: ICON 6 [30] 
3 arm study: CT with placebo vs CT + cediranib followed by placebo 
maintenance vs CT + cediranib followed by cediranib maintenance 
First relapse PSROC 11.0 vs 8.7 
HR 0.56; p<0.0001 
 
CP – carboplatin /paclitaxel; CT – platinum-based chemotherapy; PRROC – ‘platinum-resistant’ recurrent ovarian cancer;  
PSROC – ‘platinum-sensitive’ recurrent ovarian cancer 
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Table 3: PARPi trials in ovarian cancer (results awaited) 
 
Agent Trial Population Line of treatment 
Olaparib 
(Astrazeneca) 
SOLO-1 (NCT01844986): Phase III maintenance (olaparib vs placebo)  
SOLO-2 (NCT01874353): Phase III maintenance (olaparib vs placebo) 
SOLO-3 (NCT02282020): Phase III olaparib vs physician choice CT (standard of 
care non-platinum based) 
BRCAmut; AOC 
BRCAmut; PSROC 
BRCAmut; PSROC 
First line 
After  ≥2 lines platinum based CT 
After ≥2 lines of platinum based CT  
Rucaparib 
(Clovis) 
ARIEL 2 (part 2) (NCT01891344): Single arm study 
ARIEL 3 (NCT01968213): Phase III maintenance (rucaparib vs placebo)  
ARIEL 4 (NCT02855944): Phase III rucaparib vs chemotherapy  
HGROC 
HGROC 
BRCAmut; ROC 
Received ≥2 prior lines of CT 
After ≥2 lines of platinum based CT 
Received ≥2 lines prior CT 
Niraparib 
(Tesaro) 
QUADRA study (NCT02354586):  Single arm phase II study 
PRIMA study (NCT02655016): Phase III maintenance (niraparib vs placebo) 
AVANOVA study (NCT02354131): Phase I/II niraparib +/- bevacizumab 
HGROC 
HRD +ve;  AOC 
HRD+ve; PSROC 
Must have had 3/4 prior lines of CT 
First line 
No limits on number of previous lines of CT 
Veliparib 
(AbbVie) 
Phase III combination CT followed by maintenance (NCT02470585) 
 
BRCAmut ; AOC First line 
Talazoparib 
(Medivation/ 
Pfizer) 
Phase I/II study (NCT01989546) 
 
Phase II study (NCT02326844) 
BRCAmut solid tumours 
 
gBRCAmut ; ROC 
After  ≥ 1 standard CT OR no standard Rx 
options 
Progression following a PARPi 
 
CT – chemotherapy; Ph – phase; gBRCAm – germline BRCA mutation; PSROC – ‘platinum sensitive’ recurrent ovarian cancer; HGROC – high grade recurrent ovarian 
cancer; HRD – homologous recombination deficient; AOC – advanced ovarian cancer; Rx – treatmen
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Table 1: Phase III trials of bevacizumab in advanced ovarian cancer. 
Study Population Treatment Median PFS (months) Median OS (months) 
ICON7 [9] 
 
First-line high risk stage I-IIA 
or stage IIB-IV ovarian 
cancer (n=1528) 
CP vs CP + bevacizumab (7.5mg/kg) followed 
by maintenance bevacizumab 
22.4 vs 24.1 
(HR 0.87; p=0.04) 
58.6 vs 58.0 (p=0.85) 
Poor prognosis group:  
30.2 vs 39.7 (p=0.03) 
GOG 218 [10] 
 
First-line stage III 
(incompletely resected) and 
stage IV ovarian cancer 
(n=1873) 
CP vs CP + bevacizumab (15mg/kg) + 
maintenance + PL vs CP + bevacizumab 
(15mg/kg) + maintenance bevacizumab 
10.3 vs 11.2 vs 14.1 
(HR 0.72; p<0.001) 
39.3 vs 38.7 vs 39.7  
(HR 0.95; p=0.45) 
OCEANS [13] 
 
PSROC (n=484) GC + PL vs GC + bevacizumab (15mg/kg) 8.4 vs 12.4  
(HR 0.48; p<.0001) 
32.9 vs 33.6 
(HR 0.95; p=0.65) 
GOG 0213 [14] 
 
PSROC (n=674) CP vs CP + bevacizumab (15mg/kg) 10.4 vs 13.8  
(HR 0.61; p<.0001) 
37.7 vs 42.2  
(HR 0.83; p=0.056) 
AURELIA [15] 
 
PRROC (n= 361) CT vs CT + bevacizumab (10mg/kg q2/52 or 
15mg/kg q3/52) 
3.4 vs 6.7  
(HR 0.48; p<.001) 
13.3 vs 16.6  
(HR 0.85; p<.174) 
 
PSROC – ‘platinum-sensitive’ recurrent ovarian cancer; PRROC – ‘platinum-resistant recurrent’ ovarian cancer; CP – carboplatin/paclitaxel;  
PL – placebo; GC – gemcitabine/carboplatin; CT – chemotherapy [ choice of weekly paclitaxel, PLD, topotecan];  
q2/52 – 2 weekly; q3/52 – 3 weekly; 
 
Table
Table 2: VEGFR-Inhibitors in ovarian cancer 
Agent Trial Line of treatment PFS (months) 
Sorafenib  
 
Randomised phase II [94] 
CP +/- sorafenib followed by maintenance sorafenib for a total of 1yr 
First line  15.4 vs 16.3 
(p=0.38) 
Pazopanib  Randomised Phase II: MITO 11 [24] 
Pazopanib + paclitaxel vs paclitaxel alone 
Phase III maintenance study: AGO-OVAR-16 [25] 
Pazopanib v placebo maintenance 
PRROC 
 
First line 
6.3 vs 3.4  
 
17.9 vs 12.3  
HR 0.77; p=0.0021 
Nintedanib Phase III: AGO-OVAR-12 [28] 
CP +/- nintedanib followed by maintenance nintedinib or placebo  
First line 17.2 vs 16.6 
HR 0.84; p=0.024 
Cediranib Phase III: ICON 6 [30] 
3 arm study: CT with placebo vs CT + cediranib followed by placebo 
maintenance vs CT + cediranib followed by cediranib maintenance 
First relapse PSROC 11.0 vs 8.7 
HR 0.56; p<0.0001 
 
CP – carboplatin /paclitaxel; CT – platinum-based chemotherapy; PRROC – ‘platinum-resistant’ recurrent ovarian cancer;  
PSROC – ‘platinum-sensitive’ recurrent ovarian cancer 
 
 
 
 
Table 3: PARPi trials in ovarian cancer (results awaited) 
 
Agent Trial Population Line of treatment 
Olaparib 
(Astrazeneca) 
SOLO-1 (NCT01844986): Phase III maintenance (olaparib vs placebo)  
SOLO-2 (NCT01874353): Phase III maintenance (olaparib vs placebo) 
SOLO-3 (NCT02282020): Phase III olaparib vs physician choice CT (standard of 
care non-platinum based) 
BRCAmut; AOC 
BRCAmut; PSROC 
BRCAmut; PSROC 
First line 
After  ≥2 lines platinum based CT 
After ≥2 lines of platinum based CT  
Rucaparib 
(Clovis) 
ARIEL 2 (part 2) (NCT01891344): Single arm study 
ARIEL 3 (NCT01968213): Phase III maintenance (rucaparib vs placebo)  
ARIEL 4 (NCT02855944): Phase III rucaparib vs chemotherapy  
HGROC 
HGROC 
BRCAmut; ROC 
Received ≥2 prior lines of CT 
After ≥2 lines of platinum based CT 
Received ≥2 lines prior CT 
Niraparib 
(Tesaro) 
QUADRA study (NCT02354586):  Single arm phase II study 
PRIMA study (NCT02655016): Phase III maintenance (niraparib vs placebo) 
AVANOVA study (NCT02354131): Phase I/II niraparib +/- bevacizumab 
HGROC 
HRD +ve;  AOC 
HRD+ve; PSROC 
Must have had 3/4 prior lines of CT 
First line 
No limits on number of previous lines of CT 
Veliparib 
(AbbVie) 
Phase III combination CT followed by maintenance (NCT02470585) 
 
BRCAmut ; AOC First line 
Talazoparib 
(Medivation/ 
Pfizer) 
Phase I/II study (NCT01989546) 
 
Phase II study (NCT02326844) 
BRCAmut solid tumours 
 
gBRCAmut ; ROC 
After  ≥ 1 standard CT OR no standard Rx 
options 
Progression following a PARPi 
 
CT – chemotherapy; Ph – phase; gBRCAm – germline BRCA mutation; PSROC – ‘platinum sensitive’ recurrent ovarian cancer; HGROC – high grade recurrent ovarian 
cancer; HRD – homologous recombination deficient; AOC – advanced ovarian cancer; Rx – treatment  
PRACTICE POINTS: 
 Bevacizumab is licensed for use in ovarian cancers.   Variation in precise indications 
in the ovarian cancer treatment pathway exist in different parts of the world but the 
drug will increase tumour response rate and extend progression-free survival. 
 There are no predictive markers for benefit but one trial, ICON7 in the first-line 
setting demonstrated a survival benefit in patients with a poorer prognosis.  
 In ‘platinum-resistant’ disease, the addition of bevacizumab to chemotherapy 
improves the tumour response rate, progression-free survival and patient-reported 
outcomes. 
 BRCA mutations are the first predictive markers for response to PARP inhibitors in 
ovarian cancer. Olaparib is the first-in-class drug to be licensed for the treatment of 
ovarian cancer as maintenance therapy in platinum-sensitive ovarian cancer with a 
BRCA mutation.  
 In USA the drug is licensed as a single agent, in patients with a BRCA mutation who 
have received ≥3 lines of chemotherapy 
 
Practice Points
 1 
RESEARCH AGENDA: 
There has been a rapid expansion of new drugs targeting tumour cell growth and survival 
pathways. Whilst chemotherapy continues to be a valuable therapeutic approach, the 
incorporation of these new molecularly targeted drugs into treatment is a research priority 
This will involve: 
 Having a better understanding of the pathway control mechanisms 
 Developing trials to evaluate activity rapidly, using newer endpoints. Dose escalation 
is being replaced by target activation and novel response endpoints 
 Identification of markers predictive of response is a priority 
 Molecularly targeted agents, sequentially or in combination are likely to be most 
effective and designing trials to evaluate these are challenging
Research Agenda
 2 
 
Multiple Choice Questions: 
 
1. Which of the following statements about bevacizumab are true: 
a. It is a fusion protein that binds to VEGF  
b. Has been shown to improve progression free survival in women with high risk 
disease when given in combination with first line chemotherapy followed by 12 
months maintenance therapy 
c. Trials failed to show benefit in ‘platinum-resistant’ recurrent ovarian cancer 
d. Toxicities of bevacizumab include increased risk of bowel perforation, fistulae 
formation, impaired wound healing, increased risk of thromboembolism and 
hypertension 
e. Measurement of predictive markers allow the selection of patients who will 
benefit. 
 
      Answers:  
a) F – bevacizumab is a recombinant monoclonal antibody that binds to circulating 
VEGF-A; Aflibercept is a fusion protein that binds to VEGF preventing it from 
binding to its receptors 
 
b) T –ICON7 and GOG 218 are the two key first-line studies investigating the 
addition of bevacizumab to chemotherapy following surgery.  High-risk disease is 
defined as incomplete cytoreductive surgery (>1cm residual disease) or FIGO stage 
IV disease.  PFS for this population was 14.5 months in the chemotherapy alone arm 
vs 18.1 months in the chemotherapy plus bevacizumab arm.  No OS benefit was seen 
in these trials.  
MCQs
c) F – AURELIA study adding bevacizumab to chemotherapy in ‘platinum-resistant’ 
relapse showed significant improvement in tumour response rate, progression free 
survival and patient-reported outcome. 
 
d) T – these are the main toxicities of all VEGF inhibitors. It is important to carefully 
select patients for treatment with bevacizumab as those with extensive serosal disease 
are at high risk of bowel perforation. 
  
e) F – There are no predictive markers to select which patients will benefit. 
 
2. Which of the following are considered to be novel targets in ovarian cancer? 
a. Oestrogen and progesterone receptors 
b. Folate receptor 
c. Wee 1 
d. BRAF 
e. PARP 
 
Answers:  
a) F – oestrogen and progesterone receptors are targets for inhibition in the  
treatment of breast cancer.  Tamoxifen and aromatase inhibitors can be used in the 
treatment of ovarian cancer, particularly low-grade serous cancers. However, it is 
unclear whether oestrogen/progesterone receptor status in these tumours influences 
the benefit of these drugs 
 
b) T – Farletuzumab and vintafolide both target the folate receptor and have been 
evaluated in the treatment of ovarian cancer.  However, they have not been shown to 
improve survival. 
 
c) T - Wee1 is a tyrosine kinase that is required for normal functioning of the G2 
checkpoint in the cell cycle.  Wee1 inhibitors, when combined with carboplatin, have 
shown promising activity in ‘platinum-resistant’ ovarian cancer with p53 mutations.  
 
d) F – BRAF mutations lead to activation of the MAPK signalling pathway and are 
commonly found in a number of cancers.  BRAF inhibitors are approved in the 
treatment of malignant melanoma and are being investigated in clinical trials for 
other BRAF-mutant cancers.  BRAF inhibitors are currently not being evaluated in 
the treatment of ovarian cancer. 
 
e) T – Poly ADP ribose polymerase (PARP) is an enzyme involved in DNA damage 
repair.  PARP inhibitors have been shown improve outcomes in ovarian cancers with 
homologous recombination deficiency, particularly those with BRCA mutations.   
 
 
 
 
 
 
 
 
  
 
3. Which of the following statements related to homologous recombination deficiency 
(HRD) in ovarian cancer are true? 
a. Single strand DNA breaks are the most lethal insult to the genome 
b. Germline BRCA mutations are present in 50% of high grade serous ovarian 
cancer 
c. Olaparib only improves PFS in BRCA mutated ovarian cancer, but has no 
activity in BRCA
wt 
cancer 
d. PARP inhibitors are well tolerated, with the most common toxicities being 
nausea, vomiting, fatigue and anaemia 
e. The most evidence for the use of PARP inhibitors is in the ‘platinum- sensitive’ 
setting 
 
Answers: 
a) F – Double strand DNA breaks (DSB) are the most lethal insult to the genome and 
if left unrepaired, cell death will occur.  
 
b) F – germline BRCA mutations are found in 10-15% of high-grade serous ovarian 
cancers.  Approximately 50% of high-grade serous tumours have HRD and 
behave like BRCA mutated cancer (‘BRCAness’) 
 
c) F – study 19 is the original trial evaluating the use of olaparib as maintenance 
therapy in high-grade serous ovarian cancer after completion of platinum based 
therapy.  BRCA status was unknown at the time of study entry, but was analysed 
retrospectively in a pre-specified analysis.  In the BRCA
 
mutated (germline or 
somatic ) group of patients, the median PFS was significantly longer in the 
olaparib group compared to the placebo group.  However, there was also a 
benefit seen in the BRCA
 
wild-type group.   
 
d) T – PARP inhibitors are oral tablets, which are generally well tolerated.  
 
e) T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
4. The role of immunotherapy in ovarian cancer is currently being evaluated in 
multiple trials.  Which of the following statements are true? 
a. PD-1 and PDL-1 enable cancer cells to ‘escape’ the immune system 
b. Tumour infiltrating cells are poor prognostic indicators in ovarian cancer 
c. Pembrolizumab is a humanized monoclonal anti-PD-1 antibody, 
d. Immune checkpoint inhibitors have shown encouraging response rates of > 
20% in patients with ‘platinum-sensitive’ recurrent ovarian cancer 
e. Common adverse events include fatigue, flu-like symptoms, infusion-related 
reactions, rash and hypothyroidism. 
 
Answers: 
 
a) T - Tumour cells are able to ‘escape’ the immune system and one of the most 
important components is an immunosuppressive co-signal (immune checkpoint) 
facilitated by programmed cell death 1 (PD-1) and it’s ligand PDL-1 
 
b) F - In ovarian cancer, the presence of tumour infiltrating lymphocytes (TILs) is 
prognostic for better survival; a high number of immunosuppressive regulatory T-
cells (Tregs) are associated with a poor prognosis 
 
c) T – Pembrolizumab and nivolumab are anti-PD-1 antibodies and avelumab is a 
fully humanised anti-PDL-1 antibody  
 
d) F – The JAVELIN Solid tumour phase Ib (avelumab) study in multiple tumours 
reported an overall response rate of 9.7% in patients with heavily pre-treated 
‘platinum-resistant’ ovarian cancer.  KEYNOTE-028 study with pembrolizumab 
reported an overall response rate of 11.5%.  
 
e) T 
 
 
 
 
 
 
 
 
